Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

TCR-induced alteration of primary MHC peptide anchor residue.

Madura F, Rizkallah PJ, Legut M, Holland CJ, Fuller A, Bulek A, Schauenburg AJ, Trimby A, Hopkins JR, Wells SA, Godkin A, Miles JJ, Sami M, Li Y, Liddy N, Jakobsen BK, Loveridge EJ, Cole DK, Sewell AK.

Eur J Immunol. 2019 Jul;49(7):1052-1066. doi: 10.1002/eji.201948085. Epub 2019 May 27.

2.

Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells.

Mimitou EP, Cheng A, Montalbano A, Hao S, Stoeckius M, Legut M, Roush T, Herrera A, Papalexi E, Ouyang Z, Satija R, Sanjana NE, Koralov SB, Smibert P.

Nat Methods. 2019 May;16(5):409-412. doi: 10.1038/s41592-019-0392-0. Epub 2019 Apr 22.

3.

Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells.

Dolton G, Zervoudi E, Rius C, Wall A, Thomas HL, Fuller A, Yeo L, Legut M, Wheeler S, Attaf M, Chudakov DM, Choy E, Peakman M, Sewell AK.

Front Immunol. 2018 Jun 29;9:1378. doi: 10.3389/fimmu.2018.01378. eCollection 2018.

4.

Nonstimulatory peptide-MHC enhances human T-cell antigen-specific responses by amplifying proximal TCR signaling.

Zhao X, Sankaran S, Yap J, Too CT, Ho ZZ, Dolton G, Legut M, Ren EC, Sewell AK, Bertoletti A, MacAry PA, Brzostek J, Gascoigne NRJ.

Nat Commun. 2018 Jul 13;9(1):2716. doi: 10.1038/s41467-018-05288-0.

5.

Designer T-cells and T-cell receptors for customized cancer immunotherapies.

Legut M, Sewell AK.

Curr Opin Pharmacol. 2018 Aug;41:96-103. doi: 10.1016/j.coph.2018.05.005. Epub 2018 May 29. Review.

PMID:
29852403
6.

Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.

Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM, Ott S, Connor T, Szomolay B, Dolton G, Sewell AK.

J Immunol. 2018 Apr 1;200(7):2263-2279. doi: 10.4049/jimmunol.1700242. Epub 2018 Feb 26.

7.

Dual Molecular Mechanisms Govern Escape at Immunodominant HLA A2-Restricted HIV Epitope.

Cole DK, Fuller A, Dolton G, Zervoudi E, Legut M, Miles K, Blanchfield L, Madura F, Holland CJ, Bulek AM, Bridgeman JS, Miles JJ, Schauenburg AJA, Beck K, Evavold BD, Rizkallah PJ, Sewell AK.

Front Immunol. 2017 Nov 10;8:1503. doi: 10.3389/fimmu.2017.01503. eCollection 2017.

8.

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA.

Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.

PMID:
29131157
9.

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.

Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK.

Blood. 2018 Jan 18;131(3):311-322. doi: 10.1182/blood-2017-05-787598. Epub 2017 Nov 9.

10.

PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.

Donia M, Kjeldsen JW, Andersen R, Westergaard MCW, Bianchi V, Legut M, Attaf M, Szomolay B, Ott S, Dolton G, Lyngaa R, Hadrup SR, Sewell AK, Svane IM.

Clin Cancer Res. 2017 Oct 1;23(19):5779-5788. doi: 10.1158/1078-0432.CCR-16-1692. Epub 2017 Jul 5.

11.

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL.

Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015.

12.

The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy.

Legut M, Cole DK, Sewell AK.

Cell Mol Immunol. 2015 Nov;12(6):656-68. doi: 10.1038/cmi.2015.28. Epub 2015 Apr 13. Review.

13.

The T cell antigen receptor: the Swiss army knife of the immune system.

Attaf M, Legut M, Cole DK, Sewell AK.

Clin Exp Immunol. 2015 Jul;181(1):1-18. doi: 10.1111/cei.12622. Epub 2015 May 14. Review.

14.

Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies.

Legut M, Lipka D, Filipczak N, Piwoni A, Kozubek A, Gubernator J.

Int J Nanomedicine. 2014 Jan 23;9:653-68. doi: 10.2147/IJN.S54911. eCollection 2014. Erratum in: Int J Nanomedicine. 2015;10:5769.

15.

Vitamin C-driven epirubicin loading into liposomes.

Lipka D, Gubernator J, Filipczak N, Barnert S, Süss R, Legut M, Kozubek A.

Int J Nanomedicine. 2013;8:3573-85. doi: 10.2147/IJN.S47745. Epub 2013 Sep 23.

Supplemental Content

Support Center